Summary The bcl-2 gene is overexpressed in the absence of gene rearrangements in most cases of B-cell chronic lymphocytic leukaemia (B-CLL) and the proto-oncogene product Bc1-2 has been shown to be a regulator of apoptosis. The activity of this protein is opposed by Bax, a homologous protein that accelerates the rate of cell death. B-lymphocyte Bcl-2 and Bax protein levels were found to be significantly altered in B-CLL and increased Bcl-2/Bax ratios were observed in both the treated and untreated patients compared with those of normal controls. These alterations were particularly pronounced in those treated patients found to be clinically unresponsive to chemotherapy. In order to determine whether Bcl-2/Bax ratios affected cell survival via an anti-apoptotic mechanism, cell death was induced in B-CLL cells in vitro using chlorambucil, and apoptosis was monitored by Annexin V and propidium iodide staining. Confirmation that the labelled cells were apoptotic was achieved by morphological assessment of cytospin preparations of cell-sorted populations. Drug-induced apoptosis in B-CLL cells was inversely related to Bcl-2/Bax ratios.
B-cell chronic lymphocytic leukaemia (B-CLL) is characterized by the accumulation in the blood, bone marrow, lymph nodes and spleen of a clonal population of non-dividing, usually CD5+, Blymphoctyes that weakly express surface immunoglobulin and surface markers of B-cell differentiation (CD19, CD20 and CD40). The clonal expansion appears to be due to the extended survival of resting monoclonal B-cells rather than to an increase in their proliferative activity. Despite a long half-life in vivo, B-CLL cells typically undergo rapid apoptosis during short-term culture (Robertson and Plunkett, 1993) .
It has been suggested for several years that the bcl-2 family of proto-oncogenes plays a central role in the development of certain malignancies, including B-CLL. Bcl-2 protein has been consistently found to be up-regulated in B-CLL and is thought to be involved in an anti-apoptotic mechanism that facilitates B-CLL cell survival (Gottardi et al, 1995) . However, recent reports have shown that the dysregulation of Bax, an antagonistic homologue of Bcl-2, may in fact be more crucial to the maintenance of this condition (Pepper et al, 1996; Thomas et al, 1996) . In any event it would appear that the Bcl-2/Bax ratio may be of primary importance when determining whether cells are resistant or sensitive to treatment. As most chemotherapeutic drugs exert their cell killing effect through the induction of apoptosis, it seems likely that Bcl-2 and Bax influence the ability of cells to undergo apoptotic cell death (Reed, 1995) . This present study was designed to examine the relationship between Bcl-2/Bax ratios, clinical resistance and in vitro apoptosis in patients with B-CLL. (Cheson et al, 1988) , and clinical staging was based on the Binet system (Binet et al, 1981) . All previously treated patients had received chlorambucil therapy and four were defined as refractory based on failure to meet standard response criteria (Cheson et al, 1988) .
Peripheral blood lymphocytes were isolated by density centrifugation on Ficoll-Hypaque (Sigma, UK) and were washed three times in phosphate-buffered saline (PBS). Aliquots of the lymphocytes to be cultured were then resuspended in Eagle medium (Gibco, UK) at a concentration of 1x106 cells ml-1 and incubated at 37°C in a 5% carbon dioxide atmosphere for 48 h.
Bcl-2 and Bax analysis
Separated peripheral blood lymphocytes were analysed by triplecolour immunofluorescent staining for bcl-2, bax and CD19 (pan-Bcell marker). Approximately 1x106 cells were incubated with 10 ,ul of anti-CD19 Cy5 PE-conjugated antibody or an isotype-negative control (DAKO, UK). The cells were then fixed using a commercially available kit, 'Fix & Perm' (Caltag, USA), washed in PBS and centrifuged at 300 g for 5 min. The pelleted cells were resuspended in permeabilization solution and incubated with 10l1 of each antibody or isotype-negative control, i.e. Bcl-2 FITC (DAKO, UK) and Bax (Santa Cruz, USA). The cells were washed again and incubated with a PE-labelled secondary antibody for the Baxstained cells (Serotec, UK). Finally, the cells were washed, centrifuged at 300 g for 5 min and resuspended in 0.5 ml of 1% 
Measurement of in vitro apoptosis
Cells were cultured as described previously and were rendei apoptotic by using chlorambucil at doses of 1, 2, 3 and 5 ,ug m Spontaneous apoptosis was measured in cultured cells that w not exposed to drug. Double-staining for FITC-Annexin V bind: and for cellular DNA using propidium iodide (PI) was perfom as follows. After washing three times in PBS, the cultured c( were resuspended in binding buffer (10 mM Hepes/sodii hydroxide, pH 7.4, 140 mM sodium chloride, 2.5 mm calcil chloride). FITC-Annexin V was added to a final concentration 1 jg ml-' and the cells were incubated in the dark for 10 min. 1 cells were then washed again in PBS, centrifuged at 300g g resuspended in binding buffer (100 ,ul). Before flow cytomel analysis 10 gl of PI (10 jig ml-' in binding buffer) was added each sample. Confirmation that the labelled cells were apoptc was achieved by morphological assessment of cytospin prepa tions of cell-sorted populations.
Statistical analysis
The data obtained in these experiments were evaluated using Student's t-test and correlation coefficients were calculated fri least-squares linear regression plots. In vitro apoptosis and clinical resistance in B-CLL 937
RESULTS

Bcl-2 and Bax protein expression
Bcl-2 and Bax protein expression was determined by triple-colour immunofluorescence of peripheral blood lymphocyte samples from 22 B-CLL patients using flow cytometry. The results were expressed as MESF of the antibody staining and were compared with levels of Bcl-2 and Bax protein determined previously in peripheral blood B-lymphocytes from healthy donors (Pepper et al, 1996) . The MESF for both Bcl-2 and Bax for each patient were then used to calculate the Bcl-2/Bax ratio (Figure 1 ).
Bcl-2/bax ratios and in vivo responsiveness
The ten treated patients were assessed for Bcl-2 and Bax protein expression in this present study. Four had been defined as refractory, based on failure to meet standard response criteria. All of these patients had elevated Bcl-2/Bax ratios, suggesting that Bcl-2/Bax ratios may be a useful prognostic indicator for chemoresistance. In addition, the untreated patients exhibited a wide range of Bcl-2/Bax ratios, some of which were within the normal control range established previously (Pepper et al, 1996) . It may be that these patients represent a subset of B-CLL patients whose disease has greater sensitivity to chemotherapy.
Measurement of in vitro apoptosis
Apoptotic cells exclude all those dyes that are in use for cell viability assays, such as PI, while necrotic cells do not. However, late-stage apoptotic cells also undergo cell membrane damage in vitro and so these cells will also stain positive for PI. This finding was confirmed by analysis of cell-sorted fractions of the 'doublepositive' cells in the form of cytospins. Characteristic apoptotic bodies were observed together with increased granularity and a markedly shrunken appearance (not shown). Figure 2 shows the results of bivariate FITC-Annexin V/PI flow cytometry of B-CLL cells after incubation with chlorambucil for 48 h. The lower left quadrant of the histograms shows the viable cells, which exclude PI and are negative for FITC-Annexin V binding. The lower right quadrant represents the early apoptotic cells, which are PI negative and Annexin V positive, indicating the translocation of phosphatidyl serine to the extermal cell surface but integrity of the cytoplasmic membrane (Vermes et al, 1995) . The upper right quadrant represents the non-viable necrotic and late-stage apoptotic cells, which are positive for Annexin V binding and PI uptake. The number of apoptotic and necrotic cells increased with increasing drug concentration, and ID50 values were calculated by plotting drug concentration against log of percentage viable cells. Figure 3 shows ID values and Bcl-2/Bax ratios of treated and untreated patients. When the Bcl-2/Bax ratios were correlated with chlorambucil ID50 values, a significantly higher correlation coefficient was obtained (r = 0.9702). This would indicate that the combined ratio of the two proteins is more significant in determining the in vitro response to chemotherapy than the individual proteins alone (P = 0.0001). 
DISCUSSION
Although B-CLL cells show a decreased ability to proliferate compared with normal B-cells, they have a longer lifespan in vivo, which serves to maintain the tumour cell population. In contrast, when these cells are cultured in vitro, a significant proportion of the cells die by apoptosis (Collins et al, 1989) . Incubation with cytotoxic drugs, such as chlorambucil, accelerates this process (Begleiter et al, 1994) . The mechanism for the induction of apoptosis by these agents is yet to be determined but it seems likely that Bc1-2 and Bax proteins play important roles in determining whether cells undergo apoptosis (Oltvai et al, 1993; Reed, 1995) . Dysregulation of the Bcl-2 gene was first demonstrated in follicular lymphomas as a result of t(l4, 18) translocations. Although Bcl-2 gene rearrangements are unusual in B-CLL, high levels of Bc1-2 proteins expression have been consistently reported (Hanada et al, 1993; Thomas et al, 1996) . Robertson et al (1996) found that 25 of 44 cases (57%) had Bc1-2 expression higher than that measured in peripheral blood lymphocytes. These present data show 14 of 22 cases (64%) with elevated Bc1-2 expression.
Perhaps of more significance is the finding that 19 of 22 cases (86%) were found to express levels of Bax protein lower than those found in normal peripheral blood lymphocytes. Previous work has indicated that B-CLL cells undergo apoptosis more readily in patients with untreated, early-stage disease (Robertson and Plunkett 1993) . Recently Thomas et al (1996) evaluated B-CLL cells, using a semi-quantitative method, for their apoptotic response to drug treatment in vitro and found that cells with a high bcl-2fbax ratio were more drug resistant than cells with a low bcl-2/bax ratio. Our current data show a trend towards an apoptosis-resistant phenotype with treatment, but it remains unclear as to whether this is due to selection of a resistant population or induction of drug resistance. In addition, we have shown that Bcl-2/Bax ratios correlate with ID50 values (as measured by in vitro apoptotic cell death) and also clinical responsiveness. Therefore, it would appear that measurement of Bcl-2JBax ratios and in vitro apoptosis may be of prognostic value for determining whether a patient might be clinically resistant to cytotoxic chemotherapy.
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